Title:
MODIFIED CYTOKINES FOR USE IN CANCER THERAPY
Document Type and Number:
WIPO Patent Application WO2001061017
Kind Code:
A3
Abstract:
Cytokine derivatives capable of homing the tumoral vessels and the antigen presenting cells and the use thereof as antitumoral agents.
Inventors:
CORTI ANGELO (IT)
Application Number:
PCT/EP2001/001543
Publication Date:
January 31, 2002
Filing Date:
February 13, 2001
Export Citation:
Assignee:
SAN RAFFAELE CENTRO FOND (IT)
CORTI ANGELO (IT)
CORTI ANGELO (IT)
International Classes:
A61K8/00; A61K8/65; A61K8/96; A61K9/08; A61K9/10; A61K9/127; A61K31/70; A61K38/00; A61K38/17; A61K38/19; A61K39/395; A61K45/00; A61K9/12; A61K47/48; A61K48/00; A61P17/02; A61P35/00; A61P43/00; A61Q19/00; C07K5/093; C07K5/113; C07K7/06; C07K7/08; C07K14/525; C07K14/555; C07K14/57; C07K14/78; C07K16/30; C07K19/00; C08J3/12; C08L89/06; C12N15/09; C12N15/23; C12N15/28; (IPC1-7): C12N15/62; C12N15/28; C07K14/525; C07K14/57; A61K38/19; A61K38/21; C12N15/23; A61K31/70; C07K16/28; C07K5/08; C07K7/00; C07K5/093
Domestic Patent References:
| WO1999013329A1 | 1999-03-18 | |||
| WO1998010795A2 | 1998-03-19 |
Other References:
ARAP W ET AL: "CANCER TREATMENT BY TARGETED DRUG DELIVERY TO TUMOR VASCULATURE IN A MOUSE MODEL", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 279, 16 January 1998 (1998-01-16), pages 377 - 380, XP000857470, ISSN: 0036-8075
PASQUALINI RENATA ET AL: "Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis.", CANCER RESEARCH, vol. 60, no. 3, 1 February 2000 (2000-02-01), pages 722 - 727, XP002180667, ISSN: 0008-5472
A. GASPARRI ET AL: "Tumor pretargeting with avidin improves the therapeutic index of biotinylated Tumor Necrosis Factor alpha in mouse models", CANCER RESEARCH., vol. 59, 15 June 1999 (1999-06-15), MD US, pages 2917 - 2923, XP002180668
MORO M ET AL: "TUMOR CELL TARGETING WITH ANTIBODY-AVIDIN COMPLEXES AND BIOTINYLATED TUMOR NECROSIS FACTOR ALPHA1", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 57, no. 10, 15 May 1997 (1997-05-15), pages 1922 - 1928, XP000764022, ISSN: 0008-5472
YANG J ET AL: "A GENETICALLY ENGINEERD SINGLE-CHAIN FV/TNF MOLECULE POSSESSES THE ANTI-TUMOR IMMUNOREACTIVITY OF FV AS WELL AS THE CYTOTOXIC ACTIVITYOF TUMOR NECROSIS FACTOR", MOLECULAR IMMUNOLOGY, ELMSFORD, NY, US, vol. 32, no. 12, 1 August 1995 (1995-08-01), pages 873 - 881, XP000653177, ISSN: 0161-5890
A. CORTI ET AL: "Tumor targeting with biotinylated Tumor Necrosis factpor alpha: Structure-Acitivity relationship and mechanism of action on avidin pretargeted tumor cells.", CANCER RESEARCH., vol. 58, 1 September 1998 (1998-09-01), MD US, pages 3866 - 3872, XP002180669
CHEN WANG-QIU ET AL: "Enhanced anti-tumor effect of an IFN-gamma-EGF fusion protein.", BIOMEDICAL AND ENVIRONMENTAL SCIENCES, vol. 10, no. 4, December 1997 (1997-12-01), pages 387 - 395, XP001030801, ISSN: 0895-3988
PAGANELLI G.ET AL: "clinical application of the avidin/biotin system for tumor targeting pp.239-253", 1995, IN D. GOLDENBERG (ED. CANCER THERAPY WITH RADIOLABELED ANTIBODIES. CRC PRESS, BOCA RATON,, XP001033462
CURNIS FLAVIO ET AL: "Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13).", NATURE BIOTECHNOLOGY, vol. 18, no. 11, November 2000 (2000-11-01), pages 1185 - 1190, XP002180671, ISSN: 1087-0156
CURNIS FLAVIO ET AL: "Targeted delivery of tumor necrosis factor alpha (TNF) to tumor associated vessels.", INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, vol. 6, no. Supplement 1, 19 October 2000 (2000-10-19) - 21 October 2000 (2000-10-21), Joint Meeting of the 5th World Congress on Advances in Oncology and the 3rd International Symposium on Molecular Medicine;Crete, Greece; October 19-21, 2000, pages S72, XP001030678, ISSN: 1107-3756
PASQUALINI RENATA ET AL: "Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis.", CANCER RESEARCH, vol. 60, no. 3, 1 February 2000 (2000-02-01), pages 722 - 727, XP002180667, ISSN: 0008-5472
A. GASPARRI ET AL: "Tumor pretargeting with avidin improves the therapeutic index of biotinylated Tumor Necrosis Factor alpha in mouse models", CANCER RESEARCH., vol. 59, 15 June 1999 (1999-06-15), MD US, pages 2917 - 2923, XP002180668
MORO M ET AL: "TUMOR CELL TARGETING WITH ANTIBODY-AVIDIN COMPLEXES AND BIOTINYLATED TUMOR NECROSIS FACTOR ALPHA1", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 57, no. 10, 15 May 1997 (1997-05-15), pages 1922 - 1928, XP000764022, ISSN: 0008-5472
YANG J ET AL: "A GENETICALLY ENGINEERD SINGLE-CHAIN FV/TNF MOLECULE POSSESSES THE ANTI-TUMOR IMMUNOREACTIVITY OF FV AS WELL AS THE CYTOTOXIC ACTIVITYOF TUMOR NECROSIS FACTOR", MOLECULAR IMMUNOLOGY, ELMSFORD, NY, US, vol. 32, no. 12, 1 August 1995 (1995-08-01), pages 873 - 881, XP000653177, ISSN: 0161-5890
A. CORTI ET AL: "Tumor targeting with biotinylated Tumor Necrosis factpor alpha: Structure-Acitivity relationship and mechanism of action on avidin pretargeted tumor cells.", CANCER RESEARCH., vol. 58, 1 September 1998 (1998-09-01), MD US, pages 3866 - 3872, XP002180669
CHEN WANG-QIU ET AL: "Enhanced anti-tumor effect of an IFN-gamma-EGF fusion protein.", BIOMEDICAL AND ENVIRONMENTAL SCIENCES, vol. 10, no. 4, December 1997 (1997-12-01), pages 387 - 395, XP001030801, ISSN: 0895-3988
PAGANELLI G.ET AL: "clinical application of the avidin/biotin system for tumor targeting pp.239-253", 1995, IN D. GOLDENBERG (ED. CANCER THERAPY WITH RADIOLABELED ANTIBODIES. CRC PRESS, BOCA RATON,, XP001033462
CURNIS FLAVIO ET AL: "Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13).", NATURE BIOTECHNOLOGY, vol. 18, no. 11, November 2000 (2000-11-01), pages 1185 - 1190, XP002180671, ISSN: 1087-0156
CURNIS FLAVIO ET AL: "Targeted delivery of tumor necrosis factor alpha (TNF) to tumor associated vessels.", INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, vol. 6, no. Supplement 1, 19 October 2000 (2000-10-19) - 21 October 2000 (2000-10-21), Joint Meeting of the 5th World Congress on Advances in Oncology and the 3rd International Symposium on Molecular Medicine;Crete, Greece; October 19-21, 2000, pages S72, XP001030678, ISSN: 1107-3756
Download PDF: